I Claim:

2. (New) An intravenous pharmaceutical composition comprising an aqueous solution of arsenic trioxide and sodium chloride.

3. (New) An intravenous pharmaceutical composition of claim 2 comprising 1g to 10g of arsenic trioxide, 8g of sodium chloride dissolved in 1000mL of water.

4. (New) An intravenous pharmaceutical composition according to claim 3 comprising 10g of arsenic trioxide.

5. (New) An intravenous pharmaceutical composition comprising 10mL of the composition of claim 4 dissolved in 500mL of 10wt% glucose solution.

6. (New) A process of preparing an intravenous composition according to claim 2 comprising:

a. boiling sterile water;

b. adding arsenic trioxide to the boiling water and continuing to boil the mixture until all of the arsenic trioxide has completely dissolved;

c. adding sodium chloride to the boiling mixture; and

d. filtering the solution to ensure sterility and injectability.

7. (New) A process of preparing the intravenous composition of claim 2 comprising:

a. boiling 1000mL of sterile water for injection;

b. adding 1g to 10g of arsenic trioxide to the boiling water and continuing to boil the mixture until the arsenic trioxide has completely dissolved;

c. adding 8g of sodium chloride to the boiling mixture;

d. g.s. with sterile water for injection to 100mL; and

e. filtering the solution through a G3 glass filter funnel to ensure sterility and injectability.

8. (New) A process according to claim 7 wherein 10g of arsenic trioxide is added to the boiling water.

9. (New) A process according to claim 8 wherein 10mL of the filtered solution from step d is added to 500mL of 10wt% glucose solution.

10. (New) A method of treating cancer by administering by intravenous drip, a composition of claim 5.